Chmical Name: Travivo (Gepirone ER)
CAS Number: 83928-66-9
CAS Number: 83928-76-1
Mechanism: 5-HT1A selective partial agonist
Status: Pending FDA approval
Developer: Fabre-Kramer Pharmaceuticals
Travivo (Gepirone ER) is an antidepressant that was initially rejected by the FDA several times due to efficacy concerns. It was first rejected in 2004 and then again in 2007.The FDA reviewed Gepirone's data in 2015 and overturned their initial rejection of the drug - giving it a favorable rating.In March 2016 the FDA issued an order for Travivo (Gepirone ER) for the treatment of major depressive disorder with favorable regulations.
Mechanism of Action: The extended-release version of gepirone, Travivo (Gepirone ER), functions principally as a partial agonist of the brain's 5-HT1A serotonin receptors. Strong affinities for these receptors are exhibited by gepirone, especially in limbic system regions that are important in mood regulation. Serotonergic neurotransmission is improved by its modulation of serotonin receptor activation, which is thought to be a factor in its anxiolytic (anxiety-reducing) and antidepressant actions.
Gepirone does not impede serotonin reuptake like conventional antidepressants do, nor does it exhibit a strong affinity for other receptor systems like norepinephrine or dopamine receptors. It is a selective serotonergic drug because of the greater specificity of its effect to serotonin pathways. It is also less likely to cause drowsiness or addiction than benzodiazepines, making it a better choice for long-term treatment of depression and anxiety.
Because of the extended-release formulation's continuous release over time, patients will experience more consistent therapeutic benefits and fewer dose reminders, which will increase patient compliance.
